Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Celularity Inc. CELU

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.


Recent & Breaking News (NDAQ:CELU)

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

GlobeNewswire 1 hour ago

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

GlobeNewswire 10 days ago

Celularity Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

GlobeNewswire August 9, 2022

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

GlobeNewswire July 27, 2022

Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

GlobeNewswire June 8, 2022

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

GlobeNewswire June 3, 2022

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire May 18, 2022

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2022

Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 15, 2022

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

GlobeNewswire February 15, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

GlobeNewswire January 18, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

GlobeNewswire December 27, 2021

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

GlobeNewswire December 13, 2021

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

GlobeNewswire November 29, 2021

Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting

GlobeNewswire November 15, 2021

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 12, 2021

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021

Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021